Day: March 25, 2024

—European Patent Office Grants New Patent Covering Use of CM-101 for the Treatment of Multiple Liver Diseases including Primary Sclerosing Cholangitis— —Further Extends Protections Afforded by CM-101 Composition of Matter and Methods and Use Patents That Have Issued in the U.S., Europe, Israel and Related Territories— TEL AVIV, Israel, March 25, 2024 (GLOBE NEWSWIRE) — Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics to treat rare fibro-inflammatory diseases with high unmet need, today reported that the European Patent Office has granted a new patent for CM-101, Chemomab’s first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target that has been shown to play a critical role in the processes that drive fibrosis and inflammation....

LOS ALTOS, Calif., March 25, 2024 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that multiple presentations will be delivered on the Company’s product candidates, oxylanthanum carbonate (OLC) and UNI-494, at the 61st European Renal Association (ERA) Congress taking place May 23-26, 2024, in Stockholm, Sweden. Shalabh Gupta, MD, Chief Executive Officer of Unicycive, commented, “The ERA Congress is one of the most prominent nephrology meetings of the year, and we are excited to deliver presentations on both OLC and UNI-494. In addition to presenting preclinical data supporting both of our programs, we will also be reporting on our two clinical trials in progress. We look forward...

Figure 1Caña Brava Project: RTP magnetic anomaly map, wrapped on topography, showing the location of the exploration lines across the alteration footprints over Caña Brava 1 and Luz MariaTORONTO, March 25, 2024 (GLOBE NEWSWIRE) — Western Metallica Resources Corp. (TSXV: WMS) (“Western Metallica” or the “Company”) is pleased to provide an update on its current exploration activities aimed at advancing the recently discovered Luz Maria and Caña Brava 1 prospects, two key copper-molybdenum porphyry targets located within its 100% owned Caña Brava Project, and situated in the La Libertad Department of Northern Peru. Geophysical and field mapping crews are currently deployed at Luz Maria and Cana Brava 1, following up on previous work conducted as it relates to strong magnetic anomalies coincident with large alteration footprints,...

FLORHAM PARK, N.J., March 25, 2024 (GLOBE NEWSWIRE) — BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that the first patient has been dosed in a Phase 2 investigator-initiated trial (IIT) with Pembrolizumab, Plinabulin, BeyondSpring’s lead asset, plus Etoposide/Platinum (EP) for first-line (1L) Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) [NCT05745350]. Current treatment for first-line ES-SCLC includes EP and EP plus PD-L1 antibodies. Although the objective response rate (ORR) is high (around 60-65%), median progression free survival (PFS) remains low (< 6 months), with median overall survival at 10-13 months1,2. Therefore, 1L ES-SCLC remains a serious unmet medical need. Plinabulin, a potent...

ADM Endeavors, Inc.ADMQ: OTCQBNew Facility Expands Production Capacity by Up to 5 Times FORT WORTH, TX, March 25, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — Just Right Products Inc., the wholly owned subsidiary of ADM Endeavors (“ADM” or the “Company”) (OTCQB: ADMQ), announces that it has been granted the final building permits for its new production facility. The facility will be built in Fort Worth on a 17.5-acre site, five miles away from the current ADM operation, and is projected to be operational before the end of 2024. This development marks a significant milestone in ADM’s expansion strategy. Detailed plans covering approximately 80,000 square feet of retail and production space have been finalized, with construction set to commence immediately, weather permitting. The required custom fabricated metal...

77% of narcolepsy type 1 patients continue to experience cataplexy attacks despite being treated 64% of narcolepsy type 1 patients continue to experience excessive daytime sleepiness, as assessed by the Epworth Sleepiness Scale (ESS), despite being treated 74% of treated narcolepsy type 1 patients exhibit cognitive impairment, as assessed by the British Columbia Cognitive Complaints Inventory (BC-CCI) Depression and anxiety were experienced by 45% and 57% of narcolepsy type 1 patients, respectively NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced topline results from the CRESCENDO (Characterizing Patient Perspectives on Unmet Needs in Narcolepsy)...

Appointment Builds on the Momentum Behind Cellebrite’s Preeminent Case-to-Closure Platform and Market-Leading Investigative Solutions to Accelerate JusticeDavid Gee, Cellebrite Chief Marketing OfficerDavid Gee was appointed Chief Marketing Officer at Cellebrite.TYSONS CORNER, Va. and PETAH TIKVA, Israel, March 25, 2024 (GLOBE NEWSWIRE) — Cellebrite DI Ltd (Nasdaq: CLBT), a global leader in Digital Investigative solutions for the public and private sectors, today announced the appointment of David Gee as Chief Marketing Officer (CMO). Mr. Gee brings more than 25 years of global sales and marketing expertise and will serve as a member of Cellebrite’s executive leadership team, reporting directly to CEO Yossi Carmil. He will oversee Cellebrite’s global marketing strategy and execution to help the Company capitalize on the...

VANCOUVER, British Columbia, March 25, 2024 (GLOBE NEWSWIRE) — MAG Silver Corp. (TSX / NYSE American: MAG) (“MAG”, or the “Company”) announces that it will release results from its updated Juanicipio Technical Report (the “Report”) on Wednesday, March 27, 2024. A conference call will be held to discuss the results of the Report on Wednesday, March 27, 2024 at 8:15 a.m. Eastern Time. Conference call dial-in numbers:Canada / USA toll-free: +1-800-319-4610International: +1-604-638-5340   A live webcast will also be available at: http://services.choruscall.ca/links/magsilver202403.html About MAG Silver Corp. MAG Silver Corp. is a growth-oriented Canadian exploration company focused on advancing high-grade, district scale precious metals projects in the Americas. MAG Silver is emerging as a top-tier primary silver mining...

THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) — Ring Energy, Inc. (NYSE American: REI) (“Ring” or the “Company”) today announced its participation in an investor event hosted by Water Tower Research (“WTR”) on March 26, 2024 at 2:00 PM Eastern. As part of WTR’s ongoing Fireside Chat Series, Jeff Robertson, Managing Director at WTR, will lead an in-depth conversation with Paul McKinney, Ring’s Chairman and Chief Executive Officer. Included in the discussion will be a variety of important topics, such as striking a balance between investing to grow the existing asset base and achieving deleveraging goals; the impact the Founders assets have on capital allocation choices; are acquisitions a viable way to strengthen balance sheet metrics; and is there an ideal reinvestment rate to maximize value. Investors and other interested...